Literature DB >> 32519953

The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists.

Gökhan Kabaçam1, Murat Dayangaç2, Enver Üçbilek3, Cemal Nuri Erçin4, Fulya Günsar5, Murat Akyıldız6, Mesut Akarsu7, Mehmet Demir8, Sabahattin Kaymakoğlu9, Zeki Karasu5, Ramazan İdilman10.   

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel acute infectious disease that has rapidly reached staggering pandemic proportions. This review addresses gastroenterologists, hepatologists, liver transplant (LT) specialists, and health-care professionals working in the field of liver diseases and liver transplantation. It has been written based on a limited number of publications, recommendations of national and international liver and organ transplantation societies, and experiences of patients with COVID-19 around the world. The purpose of this review is to provide information addressing questions and concerns about COVID-19, to reveal the effects of the novel disease on patients with chronic liver disease and LT recipients, and to share information about ways in which this pandemic will affect clinical practices. We, the Turkish Association for the Study of the Liver (TASL), would like to remind you that this text is actually not a practical guide. It is imperative to act according to the standards set by health-care institutions and the Ministry of Health, Republic of Turkey.

Entities:  

Mesh:

Year:  2020        PMID: 32519953      PMCID: PMC7289168          DOI: 10.5152/tjg.2020.20413

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  20 in total

1.  Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic.

Authors:  Lorenzo D'Antiga
Journal:  Liver Transpl       Date:  2020-04-24       Impact factor: 5.799

2.  Lest we forget.

Authors:  Karim J Halazun; Russell Rosenblatt
Journal:  Am J Transplant       Date:  2020-06-21       Impact factor: 8.086

3.  Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.

Authors:  Qingxian Cai; Minghui Yang; Dongjing Liu; Jun Chen; Dan Shu; Junxia Xia; Xuejiao Liao; Yuanbo Gu; Qiue Cai; Yang Yang; Chenguang Shen; Xiaohe Li; Ling Peng; Deliang Huang; Jing Zhang; Shurong Zhang; Fuxiang Wang; Jiaye Liu; Li Chen; Shuyan Chen; Zhaoqin Wang; Zheng Zhang; Ruiyuan Cao; Wu Zhong; Yingxia Liu; Lei Liu
Journal:  Engineering (Beijing)       Date:  2020-03-18       Impact factor: 7.553

4.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

5.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period.

Authors:  Stephen M Kissler; Christine Tedijanto; Yonatan H Grad; Marc Lipsitch; Edward Goldstein
Journal:  Science       Date:  2020-04-14       Impact factor: 47.728

6.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

7.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Authors:  Xueting Yao; Fei Ye; Miao Zhang; Cheng Cui; Baoying Huang; Peihua Niu; Xu Liu; Li Zhao; Erdan Dong; Chunli Song; Siyan Zhan; Roujian Lu; Haiyan Li; Wenjie Tan; Dongyang Liu
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

Review 8.  Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.

Authors:  Kimiyasu Shiraki; Tohru Daikoku
Journal:  Pharmacol Ther       Date:  2020-02-22       Impact factor: 12.310

9.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

10.  Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.

Authors:  Oren K Fix; Bilal Hameed; Robert J Fontana; Ryan M Kwok; Brendan M McGuire; David C Mulligan; Daniel S Pratt; Mark W Russo; Michael L Schilsky; Elizabeth C Verna; Rohit Loomba; David E Cohen; Jorge A Bezerra; K Rajender Reddy; Raymond T Chung
Journal:  Hepatology       Date:  2020-07       Impact factor: 17.298

View more
  2 in total

Review 1.  The Role of Telemedicine in Surgical Specialties During the COVID-19 Pandemic: A Scoping Review.

Authors:  Mahir Gachabayov; Lulejeta A Latifi; Afshin Parsikia; Rifat Latifi
Journal:  World J Surg       Date:  2021-11-06       Impact factor: 3.352

2.  Liver dysfunction and SARS-CoV-2 infection.

Authors:  Abraham Edgar Gracia-Ramos; Joel Omar Jaquez-Quintana; Raúl Contreras-Omaña; Moises Auron
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.